340 related articles for article (PubMed ID: 32219507)
21. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.
Schimmöller L; Quentin M; Arsov C; Lanzman RS; Hiester A; Rabenalt R; Antoch G; Albers P; Blondin D
Eur Radiol; 2013 Nov; 23(11):3185-90. PubMed ID: 23756958
[TBL] [Abstract][Full Text] [Related]
22. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
23. Are T2WI PI-RADS sub-scores of transition zone prostate lesions biased by DWI information? A multi-reader, single-center study.
Zhang KS; Mayer P; Glemser PA; Tavakoli AA; Keymling M; Rotkopf LT; Meinzer C; Görtz M; Kauczor HU; Hielscher T; Stenzinger A; Bonekamp D; Hohenfellner M; Schlemmer HP
Eur J Radiol; 2023 Oct; 167():111026. PubMed ID: 37639843
[TBL] [Abstract][Full Text] [Related]
24. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
[TBL] [Abstract][Full Text] [Related]
25. Interobserver agreement of PI-RADS v. 2 lexicon among radiologists with different levels of experience.
Mussi TC; Yamauchi FI; Tridente CF; Tachibana A; Tonso VM; Recchimuzzi DZ; Leão LRS; Luz DC; Martins T; Baroni RH
J Magn Reson Imaging; 2020 Feb; 51(2):593-602. PubMed ID: 31369194
[TBL] [Abstract][Full Text] [Related]
26. Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.
Greer MD; Shih JH; Lay N; Barrett T; Kayat Bittencourt L; Borofsky S; Kabakus IM; Law YM; Marko J; Shebel H; Mertan FV; Merino MJ; Wood BJ; Pinto PA; Summers RM; Choyke PL; Turkbey B
Radiology; 2017 Dec; 285(3):859-869. PubMed ID: 28727501
[TBL] [Abstract][Full Text] [Related]
27. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of PI-RADS 4 lesions within the prostatic peripheral zone: a retrospective diagnostic accuracy study evaluating 170 lesions.
Shankar PR; Curci NE; Davenport MS
Abdom Radiol (NY); 2018 Aug; 43(8):2176-2182. PubMed ID: 29198006
[TBL] [Abstract][Full Text] [Related]
29. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.
Rosenkrantz AB; Ginocchio LA; Cornfeld D; Froemming AT; Gupta RT; Turkbey B; Westphalen AC; Babb JS; Margolis DJ
Radiology; 2016 Sep; 280(3):793-804. PubMed ID: 27035179
[TBL] [Abstract][Full Text] [Related]
30. Central zone lesions on magnetic resonance imaging: Should we be concerned?
Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
[TBL] [Abstract][Full Text] [Related]
31. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
32. Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: Most New Disagreement Stems from Scores 1 and 2.
Beetz NL; Haas M; Baur A; Konietschke F; Roy A; Hamm CA; Rudolph MM; Shnayien S; Hamm B; Cash H; Asbach P; Penzkofer T
Rofo; 2022 Aug; 194(8):852-861. PubMed ID: 35545106
[TBL] [Abstract][Full Text] [Related]
33. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
34. Impact of a Structured Reporting Template on Adherence to Prostate Imaging Reporting and Data System Version 2 and on the Diagnostic Performance of Prostate MRI for Clinically Significant Prostate Cancer.
Shaish H; Feltus W; Steinman J; Hecht E; Wenske S; Ahmed F
J Am Coll Radiol; 2018 May; 15(5):749-754. PubMed ID: 29506919
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer.
Rudolph MM; Baur ADJ; Cash H; Haas M; Mahjoub S; Hartenstein A; Hamm CA; Beetz NL; Konietschke F; Hamm B; Asbach P; Penzkofer T
Sci Rep; 2020 Sep; 10(1):15982. PubMed ID: 32994502
[TBL] [Abstract][Full Text] [Related]
37. Predicting Prostate Biopsy Outcomes: A Preliminary Investigation on Screening with Ultrahigh B-Value Diffusion-Weighted Imaging as an Innovative Diagnostic Biomarker.
Zhang K; Shen Y; Zhang X; Ma L; Wang H; An N; Guo A; Ye H
PLoS One; 2016; 11(3):e0151176. PubMed ID: 26963936
[TBL] [Abstract][Full Text] [Related]
38. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
39. Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis.
Nguyentat M; Ushinsky A; Miranda-Aguirre A; Uchio E; Lall C; Shirkhoda L; Lee T; Green C; Houshyar R
Curr Probl Diagn Radiol; 2018 Nov; 47(6):404-409. PubMed ID: 29126575
[TBL] [Abstract][Full Text] [Related]
40. Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis.
Kim SH; Choi MS; Kim MJ; Kim YH; Cho SH
AJR Am J Roentgenol; 2017 Oct; 209(4):800-805. PubMed ID: 28705064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
